Intranasal Foralumab Meets Safety Goals in MS Trial
Tiziana Life Sciences reports its drug cleared safety and neuroinflammation endpoints in a phase 2a study of non-active secondary progressive multiple sclerosis patients.
Updated on Nov. 2, 2026 in Alzheimer’s
Tiziana Life Sciences reported that intranasal foralumab met its dual safety and neuroinflammation endpoints in a phase 2a study involving patients with non-active secondary progressive multiple sclerosis. However, the 100 μg dose did not show a statistically significant difference in PET-measured neuroinflammation.
Why it matters
The results offer a mixed signal for a drug candidate targeting neuroinflammation in a progressive form of multiple sclerosis, a condition for which treatment options remain limited. The findings will inform the company's next steps with regulators as it considers further clinical development.
The Inform-MS trial enrolled 48 patients who received 50 μg or 100 μg intranasal foralumab or placebo over 12 weeks, with the 50 μg cohort showing a 0.0231 SUVR reduction versus placebo. Whether the 0.0231 reduction is clinically meaningful, and why the higher dose did not separate from placebo, has not been explained in the release.
The players
Tiziana Life Sciences
Tiziana Life Sciences is a biotechnology company headquartered in London and Boston that develops immunology-focused therapies, including intranasal foralumab.
The details
All 48 participants completed treatment with no serious adverse events linked to foralumab. Both dose cohorts showed decreases on the Modified Fatigue Impact Scale, with reductions of 6.17 points at 50 μg and 7.18 points at 100 μg, though foralumab did not show a benefit on the Expanded Disability Status Scale.
Timeline
Treatment lasted 12 weeks for participants in the Inform-MS trial.
Tiziana Life Sciences issued its release announcing the phase 2a results on November 2, 2026.
Health Landscape
Intranasal foralumab is being tested in the Inform-MS phase 2a trial as a route to target neuroinflammation in non-active secondary progressive MS, a population with fewer approved options than relapsing forms of the disease. The mixed PET and disability results place this candidate among efforts to show that neuroinflammation imaging can translate into clinical benefit.
For people living with non-active secondary progressive MS, these results do not yet point to a new approved treatment, and any eventual therapy would depend on further trials and regulatory review. Patients considering experimental options should discuss trial eligibility and risks with their neurologist.
The takeaway
The mixed results show that a drug can clear safety hurdles without yet proving a clinical benefit, so readers should weigh early-stage findings against the need for larger, longer trials before drawing conclusions about treatment value.
What happens next
Tiziana plans to engage with the FDA to discuss the results and potential path forward for further clinical development of intranasal foralumab in non-active secondary progressive MS.
Further reading
Explore more on Alzheimer’s research and related neurological conditions.
